Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.
about
Serological diagnosis of Epstein-Barr virus infection: Problems and solutionsEpstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantMolecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant.The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients.Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders.Reactivation of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation.The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients.Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients.Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Organ transplant-related lymphoma.Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease.Immunotherapy for post-transplant lymphoproliferative disease.Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriersPrevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants.Epstein-Barr virus and post-transplant lymphoproliferative disease.Epstein-Barr virus associated disease following blood or marrow transplant.Post-transplant lymphoproliferative disorder: a review.Epstein-Barr virus (EBV) load and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders.Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and SalivaPreemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning.Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease.How I treat EBV lymphoproliferation.Epstein-Barr virus: silent companion or causative agent of chronic liver disease?Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.The Effect of Antiretroviral Combination Treatment on Epstein-Barr Virus (EBV) Genome Load in HIV-Infected Patients.Monitoring of epstein-barr virus DNA load in peripheral blood by quantitative competitive PCR.Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.Fatal outcome in a patient developing Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD) without measurable disease.Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.Adoptive cellular immunotherapy for EBV lymphoproliferative disease.Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood.Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
P2860
Q26829346-2EB040BE-87FE-4C88-A5D5-FD4AA665DD55Q26861623-0FD0C5B5-B969-40E5-A5F7-3542460BC842Q33182059-0E9559CB-5789-4E09-862A-04AC2C26245DQ33762569-78F0C631-BA7B-4F34-BFD7-045A041D2EA2Q33774368-DD3231C2-D0C5-4A7F-87D3-1062AA4C0D40Q33958107-79029400-2E08-4105-AFE4-191F539FB6FCQ33974645-2361C08A-CA28-40F8-8C61-6922E6B9601BQ34244404-04113B82-6423-4317-AEB1-2F439F89D55DQ34244446-3A6A53AA-DCAC-454D-8CE7-0995C36586C7Q34271690-5267B27D-BEE6-4B85-AB96-BC7EC3CAB85AQ34427085-7D11BBAC-E70E-4013-A66A-104656B87D5CQ34622755-9E2980CC-5D07-40C0-A6B7-D53CBF6788DEQ34678091-12FA8ACC-BF59-434A-A047-ECE19CB97546Q34769887-53A14731-03FB-4708-9C39-358AE6719C78Q34786255-387309C6-87A1-4FDB-8A67-9A29EB3F7DFAQ34946254-ED931770-3650-493A-9608-6F60991E078DQ34948319-DBD54A3A-9883-497E-A5AB-8CC86D10E5EDQ35001143-074F9C4F-9F9C-456C-A057-3C44D18FF291Q35009613-C626681F-9351-4269-970F-B4CB4B051FF1Q35072245-5EC20DF5-BF26-44D5-9A1D-AFD1909EC8EBQ35079593-43A3BF0F-C867-4117-AFFB-B8E08BAA7B66Q35212272-A30C31C0-643D-4573-92FF-F3B4F2B97121Q35686903-E2AA3B78-5C18-405A-BFAE-F30799C3A500Q36389306-18FC04F8-2259-4BF2-A419-248C023C5C4EQ36746437-B7ABCBE7-FD4E-4462-96DF-4433296D076DQ37152749-FF1C8F17-D460-4ABF-BD22-56A448F5E13AQ37169324-D82C185C-CF24-4406-9D0A-A370D3F1BCC2Q37414678-784E55BF-510E-430F-8505-0ED99B94EAE3Q37784165-28462677-1D5B-49E9-BE88-BD6F99435C5DQ37793222-32666915-9BF1-40BF-A0C8-6CC4824EBA7EQ38615024-233D7C68-A870-4D19-BF26-825E2D6C4728Q39451571-A83CFCDA-A7BD-4C20-9D8E-996C19BDD86DQ40511369-AB34B300-0F13-46A2-B8F5-1B837987FB9DQ40594767-5EF19011-13B8-4908-BFF8-AD8D8755B5A6Q40924104-DBA9360E-A37F-4C64-AEEE-C1A3EEBCB624Q41561745-3301BAFF-E067-4F46-9879-59C91296A96CQ41561751-89C59F68-EA3E-4C55-ADC4-371EA4E201E9Q41946539-1A4F3DCD-DBC8-479E-BBD8-A84A5C4908A8Q44032290-A6F1E11A-8A02-46FD-8DF2-D4BFBB4D2364Q44118692-CFAE0124-5970-4DB2-8A74-7E4D89941E5F
P2860
Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Early identification of Epstei ...... n lymphoproliferative disease.
@en
Early identification of Epstei ...... n lymphoproliferative disease.
@nl
type
label
Early identification of Epstei ...... n lymphoproliferative disease.
@en
Early identification of Epstei ...... n lymphoproliferative disease.
@nl
prefLabel
Early identification of Epstei ...... n lymphoproliferative disease.
@en
Early identification of Epstei ...... n lymphoproliferative disease.
@nl
P2093
P1476
Early identification of Epstei ...... n lymphoproliferative disease.
@en
P2093
P304
P356
10.1111/J.1365-2141.1995.TB08904.X
P407
P577
1995-01-01T00:00:00Z